the role the drug may have played in that recovery is unclear.
"We have had apparent success with this patient and I'm happy she did well, but I'm not going to let my ego get ahead of myself. I still want to stick to science and I still want to see data," said Avish Nagpal, a doctor who specializes in infectious disease who is also the medical director for infection prevention at Sanford Health.
Nagpal said collection of helpful data can be accelerated if significant numbers of COVID-19 patients take part in randomized control trials of drugs like leronlimab, which he said is the best way to arrive at safe and effective treatments people can trust. https://www.inforum.com/
Clinical trials CD10 and CD12 were total failures, pretty sure Dr Avish Nagpal knows this by now...doubtful he will personally by stumping for the use of leronlimab for his patients.
Market Data 
Markets 
AI
